About Repros
Company Overview
Board of Directors and Management
Pipeline
Androxal
®
Male Fertility Maintenance/Improvement
Type II Diabetes
Publications
Proellex
®
Uterine Fibroids
Endometriosis
Publications
Clinical Trials
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
July 22, 2010
Repros Therapeutics Receives Investigational Review Board Approval to Commence Low Dose for Proellex® Study at ICON Site
June 17, 2010
NASDAQ Sets July 22, 2010 for Repros Hearing to Appeal NASDAQ Delisting Notice
June 16, 2010
Repros to Appeal NASDAQ Delisting Notice
June 11, 2010
FDA Lifts Full Clinical Hold on Repros’ Proellex®
May 17, 2010
Repros Therapeutics Inc. Reports Outcome of Annual Meeting Shareholder Vote
Terms of Use
© Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax
